Progressive conduction disease late after adriamycin treatment of lymphoma, despite normalised ejection fraction
Adriamycin (doxorubicin) chemotherapy is known for its acute and late cardiotoxic complications1. In up to 2% of patients they manifest in the form of suppressed ventricular systolic function with its well known consequences, raised filling pressures and mitral regurgitation. Its potential direct ef...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Barcaray International
2014-01-01
|
| Series: | International Cardiovascular Forum Journal |
| Online Access: | http://icfjournal.org/index.php/icfj/article/view/76/68 |
| Summary: | Adriamycin (doxorubicin) chemotherapy is known for its acute and late cardiotoxic complications1. In up to 2% of patients they manifest in the form of suppressed ventricular systolic function with its well known consequences, raised filling pressures and mitral regurgitation. Its potential direct effect on conduction disturbances, however, has not been systematically described. We present a case of a patient who had severe heart failure following adriamycin lymphoma treatment who despite full recovery of systolic left ventricular (LV) function developed progressive conduction disease that required life saving cardiac pacing. |
|---|---|
| ISSN: | 2410-2636 2409-3424 |